12.91
-0.58
(-4.30%)
May 22 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 12.65 - 13.65 |
| 52 week | 10.01 - 19.67 |
| Open | 13.45 |
| Vol / Avg. | 0.00/1.12M |
| Mkt cap | 1.40B |
| P/E | - |
| Div/yield | - |
| EPS | -1.24 |
| Shares | 108.77M |
| Beta | 1.64 |
| Inst. own | 82% |
Events
Jul 17, 2013
Q2 2013 IRONWOOD PHARMACEUTICALS INC Earnings Release
Jun 4, 2013
IRONWOOD PHARMACEUTICALS INC Annual Shareholder Meeting
- 9:00AM EDT -
May 24, 2013
Q1 2013 IRONWOOD PHARMACEUTICALS INC Earnings Release
May 14, 2013
IRONWOOD PHARMACEUTICALS INC at Bank of America Merrill Lynch Health Care Conference
Apr 23, 2013
Q1 2013 IRONWOOD PHARMACEUTICALS INC Earnings Conference Call
Mar 4, 2013
IRONWOOD PHARMACEUTICALS INC at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -2884.85% | -48.34% |
| Operating margin | -2729.12% | -48.43% |
| EBITD margin | - | -40.89% |
| Return on average assets | -135.73% | -33.09% |
| Return on average equity | -371.85% | -57.20% |
| Employees | 530 | - |
| Carbon Disclosure Rating | - | - |
Address
2nd floor, 301 Binney Street
CAMBRIDGE, MA 02142
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)
CAMBRIDGE, MA 02142
United States - Map
+1-617-6217722 (Phone)
+1-617-4940480 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.
Officers and directors
| Bryan E. Roberts PhD | Independent Chairman of the Board | |
| Peter M Hecht Ph.D. | Chief Executive Officer, Director | |
| Michael J. Higgins | Chief Financial Officer, Chief Operating Officer, Senior Vice President | |
| Mark G Currie Ph.D. | Senior Vice President, Chief Scientific Officer, President - Research and Development | |
| Thomas A. McCourt | Senior Vice President - Marketing and Sales, Chief Commercial Officer | |
| Edward P. Owens | Director | |
| George H. Conrades | Independent Director | |
| Joseph C. Cook Jr. | Independent Director | |
| David A. Ebersman | Independent Director | |
| Marsha H Fanucci | Independent Director |